Adempas and Ibs - a phase IV clinical study of FDA data

Summary:

Ibs is reported as a side effect among people who take Adempas (riociguat), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Opsumit, and have Primary pulmonary hypertension.

The phase IV clinical study analyzes which people have Ibs when taking Adempas. It is created by eHealthMe based on reports of 29,726 people who have side effects when taking Adempas from the FDA, and is updated regularly.

What is Adempas?

Adempas has active ingredients of riociguat. eHealthMe is studying from 29,740 Adempas users. Check the latest studies of Adempas.

What is Ibs?

Ibs (irritable bowel syndrome -chronic abdominal pain, discomfort, bloating) is found to be associated with 1,291 drugs and 2,072 conditions by eHealthMe. Check the latest studies of Ibs.

On Oct, 19, 2025

29,726 people reported to have side effects when taking Adempas.
Among them, 53 people (0.18%) have Ibs.

Among these 53 people:

How long have people been on Adempas when they have Ibs? *

What is the gender of people who have Ibs when taking Adempas? *

female: 84.91 %
male: 15.09 %

What is the age of people who have Ibs when taking Adempas? *

What are other drugs people take besides Adempas? *

What are other side effects people have besides Ibs? *

Diarrhea: 27 people, 50.94%
Headache (pain in head): 23 people, 43.40%
Nausea (feeling of having an urge to vomit): 20 people, 37.74%
Dyspnea (difficult or laboured breathing): 20 people, 37.74%
Hypotension (abnormally low blood pressure): 17 people, 32.08%
Oedema Peripheral (superficial swelling): 15 people, 28.30%
Dizziness: 15 people, 28.30%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 14 people, 26.42%
Fatigue (feeling of tiredness): 13 people, 24.53%
Chest Pain: 13 people, 24.53%

What are the existing conditions these people have? *

Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 33 people, 62.26%
Pulmonary Hypertension (increase in blood pressure in the lung artery): 12 people, 22.64%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 3.77%
Hepatitis C: 2 people, 3.77%
Portopulmonary Hypertension (coexistence of portal and pulmonary hypertension): 1 person, 1.89%
Pain: 1 person, 1.89%
Nausea And Vomiting: 1 person, 1.89%
Cor Pulmonale Chronic (long lasting enlargement of the right ventricle of the heart): 1 person, 1.89%
Bipolar Disorder (mood disorder): 1 person, 1.89%

* Approximation only. Some reports may have incomplete information.

Do you take Adempas and have Ibs?

- Check whether Ibs is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Adempas:

Adempas (29,740 reports)

Ibs treatments and more:

Ibs (49,221 reports)

Browse all side effects of Adempas:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Ibs:

Ibs (1,291 drugs)

Browse all the conditions that are associated with Ibs:

Ibs (2,072 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on riociguat (the active ingredients of Adempas) and Adempas (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.